Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 15, 2026Reported sale · Form 4Andrew D Dickinson, Chief Financial Officer · $468.7KOpen the filing ↗
- Oct 15, 2026Reported sale · Form 4Johanna Mercier, Chief Comm & Corp Aff Officer · $468.7KOpen the filing ↗
- Oct 15, 2026Notice of sale · Form 144JOHANNA MERCIER · Officer · $468.7KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record2,81411 flagged findings
Reported transactions (Form 4)80since Mar 10, 2026 · and 16 other holdings
Corporate events (8-K)30since Jan 31, 2020
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-20capital return (buybacks/dividends)recentOpen filing ↗“…including a limitation that restricts the Company’s ability and ability of certain of its subsidiaries to create or incur…”
- 2026-05-18capital return (buybacks/dividends)recentOpen filing ↗“…require us to purchase all or a portion (equal to $2,000 and any integral multiples of $1,000 in excess thereof) of such holder’s…”
+1 more passage from the same document
- “…Control Offer and we, or any third party making such an offer in lieu of us as described above, purchases all of such notes validly…”
- 2026-05-14capital return (buybacks/dividends)recentOpen filing ↗“…require us to purchase all or a portion (equal to $2,000 and any integral multiples of $1,000 in excess thereof) of such holder’s…”
+1 more passage from the same document
- “…Control Offer and we, or any third party making such an offer in lieu of us as described above, purchases all of such notes validly…”
- 2026-05-07capital return (buybacks/dividends)recentOpen filing ↗“…allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these…”
+1 more passage from the same document
- “…UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer Purchases of Equity Securities In the first quarter of 2020, our…”
- 2026-05-07Department of Justice inquiryrecentOpen filing ↗“…Statute and the 340B statute, laws that regulate written and verbal communications about our products, individual state laws…”
- 2026-05-07merger or acquisition eventrecentOpen filing ↗“…to 747,975 shares of our common stock through May 29, 2027 , subject to certain conditions. Item 6. EXHIBITS Reference is made to…”
+1 more passage from the same document
- “…herewith or incorporated by reference: Exhibit Number Description of Document Filed / Furnished / Incorporated by Reference…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 2,814)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
Notice of proposed sale · 2 Form 144 filings newshow all 2hide
- Oct 15, 26Form 144 ↗Notice of proposed sale new
- Oct 15, 26Form 144 ↗Notice of proposed sale new
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Sep 15, 26Form 144 ↗Notice of proposed sale
- Sep 15, 26Form 144 ↗Notice of proposed sale
Insider transaction · 7 Form 4 filingsshow all 7hide
- Aug 26, 26Form 144 ↗Notice of proposed sale
- Aug 21, 26Form 4 ↗Insider transaction
- Aug 20, 26Form 144 ↗Notice of proposed sale
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Aug 17, 26Form 144 ↗Notice of proposed sale
- Aug 17, 26Form 144 ↗Notice of proposed sale
- Aug 11, 26Form 4 ↗Insider transaction
2,814 filings on record, the oldest from Feb 14, 94.
Listing the 25 most recent filings of the 2,814 on record.
9572
- May 20, 26Took on a new financial obligation+3 more in the same filing8-K 2.03 ↗
- Feb 23, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
4 senior executive changes2024 – 2025show all 4hide
- Nov 19, 25A senior executive left or was appointed8-K 5.02 ↗
- Aug 14, 25A senior executive left or was appointed8-K 5.02 ↗
- Mar 12, 25A senior executive left or was appointed8-K 5.02 ↗
- Dec 13, 24A senior executive left or was appointed+1 more in the same filing8-K/A 5.02 ↗
- Nov 20, 24Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Jul 17, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 14, 24A senior executive left or was appointed8-K 5.02 ↗
- Feb 12, 24Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Feb 2, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Sep 14, 23Entered a material agreement+3 more in the same filing8-K 1.01 ↗
4 senior executive changes2022 – 2023show all 4hide
- May 5, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jul 28, 22A senior executive left or was appointed8-K 5.02 ↗
- May 31, 22A senior executive left or was appointed8-K 5.02 ↗
- Jan 6, 22A senior executive left or was appointed8-K 5.02 ↗
- Jan 6, 21Completed an acquisition or disposal+1 more in the same filing8-K/A 2.01 ↗
- Dec 8, 20A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
8 older filings not shown · The record reaches back to Dec 21, 04.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.8.2%Mar 31, 25SCHEDULE 13G/A ↗
- Vanguard Capital Management7.5%Mar 31, 26SCHEDULE 13G ↗
- FMR LLC5.3%Dec 31, 25SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Capital World Investors4.3%Mar 31, 25SCHEDULE 13G/A ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 15, JOHANNA MERCIER filed notice of intent to sell up to $469K. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $469K on Oct 15, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+9 more recent notices · 9 with a later sale
- Oct 15, 26Sell$469KAndrew D DickinsonChief Financial Officer↗
- Oct 15, 26Sell$469KJohanna MercierChief Comm & Corp Aff Officer↗
- Oct 1, 26Sell$1.8MDaniel Patrick O'DayChairman & CEO↗
- Oct 1, 26Sell$446KDaniel Patrick O'DayChairman & CEO↗
- Sep 15, 26Sell$436KAndrew D DickinsonChief Financial Officer↗
- Sep 15, 26Sell$230KJohanna MercierChief Comm & Corp Aff Officer↗
- Sep 15, 26Sell$116KJohanna MercierChief Comm & Corp Aff Officer↗
- Sep 15, 26Sell$87KJohanna MercierChief Comm & Corp Aff Officer↗
- Sep 1, 26Sell$236KDaniel Patrick O'DayChairman & CEO↗
- Sep 1, 26Sell$1.2MDaniel Patrick O'DayChairman & CEO↗
- Sep 1, 26Sell$808KDaniel Patrick O'DayChairman & CEO↗
- Aug 26, 26Sell$462KANTHONY WELTERS↗
There are 9 more transactions in this stretch.
Stock compensation, tax and giftsshow the 19 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 22, 26Compensationamount n/aErin BurkhartSVP, Controllership↗
- Sep 22, 26Tax$117KErin BurkhartSVP, Controllership↗
- Sep 10, 26Compensationamount n/aAndrew D DickinsonChief Financial Officer↗
- Sep 10, 26Tax$195KAndrew D DickinsonChief Financial Officer↗
- Sep 10, 26Compensationamount n/aDaniel Patrick O'DayChairman & CEO↗
- Sep 10, 26Tax$613KDaniel Patrick O'DayChairman & CEO↗
- Sep 10, 26Compensationamount n/aDietmar BergerChief Medical Officer↗
- Sep 10, 26Tax$38KDietmar BergerChief Medical Officer↗
- Sep 10, 26Compensationamount n/aJohanna MercierChief Comm & Corp Aff Officer↗
- Sep 10, 26Tax$195KJohanna MercierChief Comm & Corp Aff Officer↗
- Sep 10, 26Compensationamount n/aWettan Keeley M CainEVP Gen Counsel, Legal & Comp↗
- Sep 10, 26Tax$41KWettan Keeley M CainEVP Gen Counsel, Legal & Comp↗
- Aug 26, 26Compensation$468KANTHONY WELTERS↗
- Aug 26, 26Compensation$631KANTHONY WELTERS↗
- Aug 20, 26Compensation$79KJeffrey Bluestone↗
- Aug 20, 26Compensation$122KJeffrey Bluestone↗
- Aug 20, 26Compensation$112KJeffrey Bluestone↗
- Aug 20, 26Compensation$2KJeffrey Bluestone↗
- Aug 20, 26Compensation$21KJeffrey Bluestone↗
The full record holds 487 transactions and goes back to Dec 30, 22.
Its sector and its market
Gilead Sciences Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Gilead Sciences Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Gilead Sciences Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 2,814 documents on file, from Feb 14, 1994 to Oct 16, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.